Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael Lincoff

Showing results (171-180 of 353) with videos related to

Pageof 36
Sort By:
The American Journal of Cardiology|August 10, 2019
Effect of Left Ventricular Conduction Delay on All-Cause and Cardiovascular Mortality (from the PRECISION Trial)Erich L Kiehl, Venu Menon, Kyle T Mandsager, et al.
Clinical Cardiology|March 12, 2014
Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosisKenneth W Mahaffey, Daniel M Wojdyla, Karen S Pieper, et al.
Journal of the American Heart Association|December 30, 2022
Femoral Vascular Closure Devices and Bleeding, Hemostasis, and Ambulation Following Percutaneous Coronary InterventionGuillaume Marquis-Gravel, Laurie-Anne Boivin-Proulx, Zhen Huang, et al.
Journal of the American College of Cardiology|July 3, 2024
Comparative Cardiovascular Benefits of Bempedoic Acid and Statin DrugsA Michael Lincoff, Kausik K Ray, William J Sasiela, et al.
Journal of Thrombosis and Thrombolysis|November 19, 2010
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndromeRichard C Becker, Kenneth W Mahaffey, Hongqiu Yang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 30, 2003
Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented modelKai Wang, Paul D Kessler, Zhongmin Zhou, et al.
The American Journal of Cardiology|November 27, 2002
Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximabDebabrata Mukherjee, Hitinder Gurm, W H Wilson Tang, et al.
Diabetes Care|November 22, 2018
Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety TrialVenu Menon, A Michael Lincoff, Stephen J Nicholls, et al.
American Heart Journal|July 11, 2006
Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trialJ Emilio Exaire, Samuel M Butman, Ramin Ebrahimi, et al.
Circulation. Cardiovascular Quality and Outcomes|October 2, 2014
β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trialSripal Bangalore, Deepak L Bhatt, Ph Gabriel Steg, et al.
Pageof 36

Showing results (171-180 of 353) with videos related to

Sort By:
Pageof 36
The American Journal of Cardiology|August 10, 2019
Effect of Left Ventricular Conduction Delay on All-Cause and Cardiovascular Mortality (from the PRECISION Trial)Erich L Kiehl, Venu Menon, Kyle T Mandsager, et al.
Clinical Cardiology|March 12, 2014
Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosisKenneth W Mahaffey, Daniel M Wojdyla, Karen S Pieper, et al.
Journal of the American Heart Association|December 30, 2022
Femoral Vascular Closure Devices and Bleeding, Hemostasis, and Ambulation Following Percutaneous Coronary InterventionGuillaume Marquis-Gravel, Laurie-Anne Boivin-Proulx, Zhen Huang, et al.
Journal of the American College of Cardiology|July 3, 2024
Comparative Cardiovascular Benefits of Bempedoic Acid and Statin DrugsA Michael Lincoff, Kausik K Ray, William J Sasiela, et al.
Journal of Thrombosis and Thrombolysis|November 19, 2010
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndromeRichard C Becker, Kenneth W Mahaffey, Hongqiu Yang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 30, 2003
Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented modelKai Wang, Paul D Kessler, Zhongmin Zhou, et al.
The American Journal of Cardiology|November 27, 2002
Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximabDebabrata Mukherjee, Hitinder Gurm, W H Wilson Tang, et al.
Diabetes Care|November 22, 2018
Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety TrialVenu Menon, A Michael Lincoff, Stephen J Nicholls, et al.
American Heart Journal|July 11, 2006
Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trialJ Emilio Exaire, Samuel M Butman, Ramin Ebrahimi, et al.
Circulation. Cardiovascular Quality and Outcomes|October 2, 2014
β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trialSripal Bangalore, Deepak L Bhatt, Ph Gabriel Steg, et al.
Pageof 36